NDAORALFOR SOLUTION
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
5/8 — Partial
DAYBUE STIX (trofinetide) by Acadia Pharmaceuticals is cytochrome p450 3a4 inhibitors [moa]. First approved in 2025.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAYBUE STIX (trofinetide) is an oral solution that functions as a cytochrome P450 3A4 inhibitor, approved in December 2025 and currently in launch phase. The drug's specific indication is not detailed in available data, but its mechanism suggests potential use in conditions requiring CYP3A4 modulation. The oral formulation enables convenient dosing for patients requiring this metabolic pathway intervention.
Growth16.4 years to LOE
Early-stage launch with zero competitive pressure creates opportunity for rapid market share capture and team expansion in commercial, medical, and medical science liaison roles.
Mechanism of Action
Cytochrome P450 3A4 Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
Started Sep 2021
15 enrolled
Rett Syndrome
Open-Label Extension Study of Trofinetide for Rett Syndrome
Started Nov 2020
77 enrolled
Rett Syndrome
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
Started Jan 2020
154 enrolled
Rett Syndrome
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
Started Nov 2019
187 enrolled
Rett Syndrome
Career Relevance
Working on DAYBUE STIX offers entry into a newly launched product with zero competitive pressure and sustained patent protection, creating visible career growth trajectory in commercial, clinical operations, and analytics roles. The 46 linked job openings reflect active team building across director-level and specialized technical functions to capitalize on first-mover advantage.
Worked on DAYBUE STIX at Acadia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.